Get Instant Biotech Diversification
Using an ETF to invest in biotechs makes a ton of sense.
Biotechnology is a notoriously volatile industry. Shares of individual firms often skyrocket or plummet based on clinical test results. Because biotechs tend to march to the beat of their own drum--share prices are much more sensitive to clinical trial results and merger activity within the sector than they are to the economic backdrop�they can be an interesting small addition to a satellite portfolio.
We think investing in the industry via an ETF makes a ton of sense. With a single transaction, investors can achieve instant diversification and mitigate the risk of being too exposed to any one firm. PowerShares Dynamic Biotech & Genome (PBE) might fit the bill for investors seeking to easily add some biotechnology exposure to their portfolios.
John Gabriel does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.